Sentinel Pilot Begins Scanning Drug Data, But Device Work Still Exploratory
This article was originally published in The Gray Sheet
Executive Summary
FDA will implement its mini-Sentinel post-market safety surveillance program for the first time, using data from an ongoing randomized trial of a diabetes drug.